Tradestie Institutional Equity Comparison Engine

CRSP vs MIRM โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

CRSP Overall Edge

CRSP Captures Institutional Edge (2โ€“2 Pillars ยท 6โ€“4 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to CRISPR Therapeutics AG (CRSP) driven by superior Valuation, Growth & Margin while MIRM counters with relative strength in Momentum & Technical, Options & Structure. Fundamentally, CRSP trades at 23.4x Forward P/E with -2058.6% operating margin (+1325.1% YoY revenue) versus MIRM at N/M Forward P/E and -21.6% operating margin (+39.6% YoY). In options structure, CRSP sits in BREAKDOWN (52nd %ile IV; Dealer Gamma Walls on Pro) against MIRM sits in BREAKDOWN (9th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner CRSP
CRSP 23.4x vs MIRM N/M Fwd P/E
Growth & Margin Winner CRSP
Op Margin -2058.6% vs -21.6% ยท YoY +1325.1% vs +39.6%
Momentum & Technical Winner MIRM
1Y -20.5% vs +34.2% ยท 52W Pos 1% vs 44%
Options & Structure Winner MIRM
BREAKDOWN (52nd %ile IV) vs BREAKDOWN (9th %ile IV)
CRSP NASDAQ
CRISPR Therapeutics AG
Biological Products, (No Disgnostic Substances)
$40.61
-3.86% 1D
Market Cap $4.1B
1M Return -17.54%
1Y Return -20.54%
Forward P/E 23.4x
Unified AI Score
48.6 / 100 HOLD
Tech 33.0 Fund 51.0 Flow 68.0 Mom 60.0
MIRM NASDAQ
Mirum Pharmaceuticals, Inc. Common Stock
Pharmaceutical Preparations
$92.92
-1.14% 1D
Market Cap $6.1B
1M Return +15.94%
1Y Return +34.17%
Forward P/E N/M
Unified AI Score
38.1 / 100 SELL
Tech 8.0 Fund 37.0 Flow 71.0 Mom 40.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: CRSP -20.54% MIRM +34.17% Spread: +54.71 pp (MIRM Lead)

Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant Revenue ($B) & Operating Margin (%)
Period CRSP Revenue MIRM Revenue CRSP Op. Margin MIRM Op. Margin Margin Edge
FY2018 $0M N/A -5087.8% N/A CRSP
FY2019 $290M N/A 16.1% N/A CRSP
FY2020 $0M N/A -49295.5% N/A CRSP
FY2021 $910M $20M 40.8% -906.1% CRSP
FY2022 $0M $80M -56190.4% -170.3% MIRM
FY2023 $370M $190M -60.0% -58.6% MIRM
FY2024 $40M $340M -1250.4% -26.0% MIRM
FY2025 $0M $520M -18933.6% -4.2% MIRM

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: CRSP (6) vs MIRM (4)
Institutional Metric CRSP MIRM Criterion Row Winner
Market Capitalization Scale $4.1B $6.1B Larger Scale MIRM
Trailing P/E Ratio Valuation 23.4x N/M Lower Multiple CRSP
Forward P/E Ratio Valuation 23.4x N/M Lower Multiple CRSP
Revenue Growth (YoY) Growth +1325.1% +39.6% Higher Growth CRSP
Operating Margin (TTM) Profitability -2058.6% -21.6% Higher Margin MIRM
Net Profit Margin Profitability 0.0% -134.8% Higher Margin CRSP
Return on Equity (ROE) Capital Efficiency -25.6% -760.0% Higher ROE CRSP
52-Week Range Position Momentum 1% ($40โ€“$63) 44% ($63โ€“$130) Stronger Trend MIRM
Beta / 30D Volatility Risk Regime 1.85ฮฒ ยท 60% Vol 1.02ฮฒ ยท 49% Vol Lower Realized Risk MIRM
Unified Institutional Score Composite Signal 48.6 / 100 (HOLD) 38.1 / 100 (SELL) Higher Composite CRSP

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full CRSP vs MIRM Buy Guide
CRSP BREAKDOWN
58d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 52nd %ile
IV Regime Balanced (25thโ€“60th %ile)
Live CRSP Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
MIRM BREAKDOWN
92d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 9th %ile
IV Regime Compressed (<25th %ile)
Live MIRM Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither CRSP nor MIRM registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.